Effects of replacing oxitropium with tiotropium on pulmonary function in patients with COPD: A randomized study

Respiratory Medicine

Volumn 101, Issue 3, 2007, Pages 476-480

  Incorvaia, Cristoforo ^a   Galeazzo Riario Sforza, Gian ^a   Pravettoni, Chiara ^a   Dugnani, Natale ^a   Paterniti, Fulvia ^a   Pessina, Laura ^a   Fumagalli, Mario ^a  

^a ICP Hospital   (Italy)

Author keywords

Anticholinergics; COPD; Drug treatment; Oxitropium; Pulmonary function; Tiotropium

Indexed keywords

OXITROPIUM BROMIDE; TIOTROPIUM BROMIDE;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; RESIDUAL VOLUME; SHORT COURSE THERAPY; SPIROMETRY;

AGED; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; FEMALE; HUMANS; LUNG; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES;

EID: 33846690157     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.07.008     Document Type: Article

References (23)

1. Pauwels R.A., Buist A.S., Calverley P.M.A., Jenkins C.R., and Hurd S.S. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLB/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop report. Am J Respir Crit Care Med 163 (2001) 1256-1276
2. Rand Sutherland E., and Cherniak R.M. Management of chronic obstructive pulmonary disease. N Engl J Med 350 (2004) 2689-2697
3. Weder M.M., and Donohue J.F. Role of bronchodilators in chronic obstructive pulmonary disease. Semin Respir Crit Care Med 26 (2005) 221-234
4. Belman M.J., Botnick W.C., and Shin J.W. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153 (1996) 67-75
5. Friedman M., Witek Jr. T.J., Serby C.W., et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared to ipratropium alone and albuterol alone in chronic obstructive pulmonary disease. Chest 115 (1999) 635-641
6. Rennard S.I., Anderson W., ZuWallack R., et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163 (2001) 1087-1092
7. Disse B., Reichl R., Speck G., Traunecker W., Rominger K.L., and Hammer R. Ba 679 Br, a novel long-acting anticholinergic bronchodilator: preclinical and clinical aspects. Life Sci 52 (1993) 537-544
8. Maesen F.P.V., Smeets J.J., Sledsens T.J.H., Wald F.D.M., and Cornelissen P.J.G. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 8 (1995) 1506-1513
9. Barnes P.J. Tiotropium bromide. Expert Opin Invest Drugs 10 (2001) 733-740
10. Casaburi R., Mahler D.A., Jones P.W., et al. A long term evaluation of once daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 217-224
11. Vincken W., van Noord J.A., Greefhorst A.P.M., et al. Improvement in health status in patients with COPD during one year treatment with tiotropium. Eur Respir J 19 (2002) 209-216
12. Brusasco V., Hodder R., Miravitlles M., Korducki L., Towse L., and Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58 (2003) 399-404
13. Casaburi R., Briggs Jr. D.D., Donohue J.F., Serby C.W., Menjoge S.S., and Witek Jr. T.J. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 118 (2000) 1294-1302
14. O'Donnell, Fluge T., Gerken F., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23 (2004) 832-840
15. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 152 (1995) 1107-1136
16. Riario-Sforza G.G., Incorvaia C., Paterniti F., Dugnani N., and Fumagalli M. Different outcome of pulmonary rehabilitation in patients with COPD with or without exacerbations. Monaldi Arch Chest Dis 63 (2005) 129-132
17. Barr R.G., Bourbeau J., Camargo C.A., and Ram F.S. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev CD002876 (2005)
18. Cazzola M., Noschese P., Salzillo A., De Giglio C., D'Amato G., and Matera M.G. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med 99 (2005) 524-528
19. Peel E.T., Anderson G., Cheong B., and Broderick N. A comparison of oxitropium bromide and ipratropium bromide in asthma. Eur J Respir Dis 65 (1984) 106-108
20. Barnes P.J. Muscarinic receptor subtypes in airways. Life Sci 52 (1993) 521-527
21. Hogg J.C., Chu F., Utokaparch S., et al. The nature of small airways obstruction in chronic obstructive pulmonary disease. N Engl J Med 350 (2004) 2645-2653
22. Celli B., ZuWallack R., Wang S., and Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 124 (2003) 1743-1748
23. Santus P., Centanni S., Verga M., Di Marco F., Matera M.G., and Cazzola M. Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation. Respir Med 100 (2006) 1277-1281